The autoimmune/inflammatory syndrome induced by adjuvants (ASIA)/Shoenfeld's syndrome: descriptive analysis of 300 patients from the international ASIA syndrome registry. — CFSMEATLAS
E3 PreliminaryPreliminaryPEM not requiredRegistry-ResourcePeer-reviewedMachine draft
Standard · 3 min
The autoimmune/inflammatory syndrome induced by adjuvants (ASIA)/Shoenfeld's syndrome: descriptive analysis of 300 patients from the international ASIA syndrome registry.
Watad, Abdulla, Quaresma, Mariana, Bragazzi, Nicola Luigi et al. · Clinical rheumatology · 2018 · DOI
Quick Summary
This study examined 300 patients who developed autoimmune diseases after exposure to adjuvants (immune-stimulating substances in vaccines and other products). The most common symptoms were joint pain, muscle pain, and chronic fatigue, and most patients developed another autoimmune condition within about 17 months of exposure. The researchers found that different adjuvants caused slightly different patterns of illness.
Why It Matters
This study is relevant to ME/CFS research because it demonstrates that adjuvant exposure can trigger sustained autoimmune and inflammatory responses with fatigue as a cardinal symptom. Understanding ASIA syndrome mechanisms may illuminate post-vaccination or post-infection autoimmune triggers in ME/CFS subgroups, and the registry methodology provides a model for systematically studying rare post-exposure conditions.
Observed Findings
Mean time between adjuvant exposure and symptom onset was 16.8 months, with a range of 3 days to 5 years.
Arthralgia, myalgia, and chronic fatigue were the most frequently reported symptoms across the cohort.
Eighty-nine percent of ASIA syndrome patients were diagnosed with another defined rheumatic or autoimmune condition.
Undifferentiated connective tissue disease (UCTD) was the most common coexisting autoimmune disease.
The majority of patients tested positive for anti-nuclear antibodies (ANA).
Inferred Conclusions
Adjuvant exposure is associated with an identifiable syndrome characterized by fatigue, arthromyalgia, and subsequent autoimmune disease development.
ASIA syndrome frequently co-occurs with UCTD and positive ANA, suggesting a shared immunological mechanism.
The clinical and laboratory phenotype varies depending on the type of adjuvant involved.
Increased clinical awareness of ASIA syndrome may help identify patients at higher autoimmune disease risk following adjuvant exposure.
Remaining Questions
What are the specific immunological mechanisms by which different adjuvants trigger aberrant autoimmune responses?
What This Study Does Not Prove
This study does not prove that adjuvants cause ME/CFS or that all ME/CFS patients have ASIA syndrome. The registry is observational and retrospective, so it cannot establish causation definitively—temporal association alone does not prove the adjuvant directly caused the autoimmune response. The study also does not address whether ASIA syndrome and ME/CFS share common pathophysiological mechanisms.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →